Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy Meeting Abstract
| Authors: | Hutson, T. E.; Bracarda, S.; Escudier, B.; Porta, C.; Figlin, R. A.; Calvo, E.; Grunwald, V.; Ravaud, A.; Kpamegan, E.; Motzer, R. J. |
| Abstract Title: | Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy |
| Meeting Title: | 2011 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2011 Feb 17-19 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-03-01 |
| Language: | English |
| ACCESSION: | WOS:000208880700311 |
| DOI: | 10.1200/jco.2011.29.7_suppl.312 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 312 -- Source: Wos |
